Physician profile
James E Van Riessen
NPI 1184721219
$24,958.88
in general payments reported to CMS, 2019-2025
44 companies · $1,851 in 2025
The $1,851 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,130 · 2020: $7,056 · 2021: $2,025 · 2022: $1,529 · 2023: $2,413 · 2024: $1,955 · 2025: $1,851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,218.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12,732.61 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,469.49 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,291.24 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $1,136.39 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $957.02 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Abbott Laboratories | $844.77 | 2021-2025 | Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $795.18 | 2019-2025 | Jardiance, Spiriva Respimat |
| Novo Nordisk INC | $785.63 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $757.78 | 2019-2025 | Trintellix |
| Amgen INC. | $623.86 | 2019-2025 | Repatha, Otezla, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $427.43 | 2019-2025 | Xifaxan |
| Allergan, INC. | $378.79 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $378.68 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $327.68 | 2019-2021 | |
| Astellas Pharma US INC | $302.42 | 2019-2025 | Veozah, Myrbetriq |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Van Riessen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.